Insights
Insights From Our Experts
Articles
Human-in-the-Loop + AI: A Pragmatic Path Forward for Pharma Commercialization
In a recent industry webinar, senior leaders from across the life sciences spectrum gathered to discuss the evolving role of artificial intelligence in commercialization. While the promise of AI is undeniable, the consensus was clear: In…
Balancing Privacy, Compliance and Personalization in Direct-to-Patient Models
In healthcare today, the direct-to-patient (DTP) model is reshaping how patients manage and control their treatment, information and support. DTP is a reorientation of existing commercialization capabilities across the patient journey, in a way that reduces…
Content Acceleration Like Never Before: Meet Our AI Agency Platform
In today’s life sciences landscape, speed and precision are no longer nice-to-haves—they’re necessities for keeping pace with the needs of patients and providers and ahead of the competition. That’s why we launched the industry’s first end-to-end,…
AI in Oncology: Acceleration, Accessibility, and Accuracy
At ESMO 2025, the conversation around artificial intelligence in oncology was impossible to ignore. From accelerating drug development to enabling remote patient monitoring, AI is completely changing cancer care— and EVERSANA has consistently leveraged these innovations…
AI at ESMO 2025: Navigating the New Frontier of Opportunity and Obstacles in Oncology
For the first time in its history, the European Society for Medical Oncology (ESMO) dedicated an entire track to Artificial Intelligence (AI) at its 2025 conference. For those who partner with pharmaceutical and biotech companies to…
Content Evolution: Shifting to Component-Based Authoring and Modular Strategies
Posted by
Mary Mehrabian, PharmD, BCGP, BCMAS , Michael DeLuca, PharmD, MBA, MSRA , Varun Pandey, PhD , Natalia Gandarillas, MPharm on October 28, 202510/28/25
The pharmaceutical industry is experiencing a major transformation in how Medical Affairs teams create and share content with healthcare professionals and patients. Gone are the days of static, one-size-fits-all materials. Today, organizations are embracing component-based authoring…
Interpretation of the Europe Regulatory Framework and Best Practices for MI Across the Pharma Industry
Posted by
Michael DeLuca, PharmD, MBA, MSRA , Varun Pandey, PhD , Lindsey Buyskes, B Pharm , Natalia Gandarillas, MPharm on October 28, 202510/28/25
Navigating the European regulatory landscape for Medical Information (MI) is no easy feat. Recent research reveals that MI teams across pharma companies—large and small—face a patchwork of requirements and best practices, from consent handling and call…
How a Strategic Global HEOR Package Drives Market Access and Pricing Success
As ISPOR Europe 2025 approaches and momentum builds around how Health Economics and Outcomes Research (HEOR) continues to evolve—shaped by innovation, policy shifts and global collaboration, I’ve been reflecting on recent global product launches. What stands…
The Future of Personalized, Measurable MSL Engagement: Key Takeaways from Susan Giacalone
Not all data is equally valuable. Strategic medical insights—those that inform strategy and improve patient outcomes—are essential. In a recent article in Med Ad News (PharmaLive), Susan Giacalone explores how Medical Science Liaisons (MSLs) are redefining…
Let’s Be DIRECT: We Have An Access and Affordability Problem to Solve
Schedule a meeting to connect with one of our experts to explore whether a direct-to-patient or direct-to-provider model could be a good fit to your brand’s access and affordability strategy. The pharmaceutical industry is at an…